Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q2 2019 Earnings Presentation

33 slides from Neurocrine Biosciences's earnings presentation, Jul 29, 2019

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2019 Corporate Presentation July 29, 2019 neurocrine.com NASDAQ: NBIX

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from Neurocrine's products and product can

  3. Slide 3: Neurocrine Q2 2019 Highlights and 2019 Key Activities

    Neurocrine Q2 2019 Highlights and 2019 Key Activities Q2 and 1H 2019 Highlights 2H 2019 Key Activities ▪ INGREZZA® Net Product Sales: ▪ INGREZZA Commercial Execution and “Talk – $181MM with 31,600 TRx in Q2 2019 About TD” Disease State Awareness Campaign – $317MM with 55,800 TRx in 1H 2019 ▪ Execute

  4. Slide 4: 2019: A Defining Year of Significant Milestones

    2019: A Defining Year of Significant Milestones 2 NDA Submissions: Parkinson’s Disease & Uterine Fibroids Opicapone (Parkinson’s disease) COMPLETED Elagolix (Uterine fibroids) submitted by AbbVie 2H 2019 Advancing Congenital Adrenal Hyperplasia Program Positive interim results from Phase II Study (a

  5. Slide 5: 2020: Potential for 3 Approved Treatments in 4 Indications

    2020: Potential for 3 Approved Treatments in 4 Indications 2018 2019 2020 2 2 APPROVED TREATMENTS 2 NEW DRUG APPLICATIONS IN INDICATIONS Opicapone Parkinson’s Disease 3 Approved treatments in Tardive Dyskinesia Endometriosis Elagolix Uterine Fibroids 4 indications ▪ Voyager Collaboration (Parkinson’

  6. Slide 6: Our Medicines, Our Patients

    w/ NeuUrocrine BIOSCIENCES Our Medicines Our Patients

  7. Slide 7: 1st FDA-approved Treatment for Tardive Dyskinesia; Launched in 2017

    1st FDA-approved Treatment for Tardive Dyskinesia; Launched in 2017 Most-Prescribed and Most-Preferred TD Therapy ▪ Rapid Improvement in Involuntary Movements ▪ Safe & Well Tolerated ▪ Ease of Use: One capsule, Once-daily Q2 2019 Earnings Presentation 7

  8. Slide 8: Tardive Dyskinesia Overview: Symptoms

    Tardive Dyskinesia Overview: Symptoms Oral and Facial Dyskinesia • Abnormal tongue and lip movements • Retractions of the corners of the mouth • Abnormal eyelid closure or eyebrow Torso Dyskinesia movements • Shoulder shrugging • Bulging of the cheeks • Chewing movement Axial Dystonia • Twisting of

  9. Slide 9: INGREZZA: Most Prescribed Tardive Dyskinesia Therapy

    INGREZZA® Most Prescribed Tardive Dyskinesia (TD) Therapy z Tardive dyskinesia Efficacy: Label: Use: affects approximately Rapid and No Boxed Convenient Dosing 500,000 patients Robust Warning in the U.S. ▪ Involuntary Movement Disorder ▪ ~30% Reduction in TD ▪ No Boxed Warning ▪ Convenient One Capsu

  10. Slide 10: Two Years Post-Launch, Expectations Exceeded

    Two Years Post-Launch, Expectations Exceeded INGREZZA Net Sales and ~TRx $180 $181 35,000 31,600 $160 30,000 16,700 $140 $130 $136 Approximate TRx Net Product Sales 25,000 24,200 ($ in Millions) $120 $111 22,900 $97 20,000 $100 19,400 $80 $71 16,700 15,000 $64 12,500 $60 $46 10,000 9,100 $40 5,000 $

  11. Slide 11: KINECT 3: Reduction in Abnormal Involuntary Movement Scores

    KINECT 3: INGREZZA® Reduction in Abnormal Involuntary Movement Scores at Each Study Visit Through Week Six AIMS Change from Baseline by Study Visit (ITT Population) WEEK 0: Baseline WEEK 2 WEEK 4 WEEK 6 n=76 n=70 n=79 n=76 n=70 n=77 n=73 n=64 n=73 n=69 n=63 n=70 LS Mean Change From Baseline (SEM) 0

  12. Slide 12: KINECT 3: AIMS Change from Baseline Long-Term Extension

    KINECT 3: AIMS Change from Baseline for INGREZZA® Groups (Long-Term Extension Period) AIMS Mean Change (SEM) from Baseline (ITT Population) 1 0 Placebo -1 INGREZZA 40 mg Improvement -2 Once Daily -3 INGREZZA 80 mg Once Daily -4 Placebo to INGREZZA -5 40 mg -6 Placebo to INGREZZA 80 mg -7 PBO Control

  13. Slide 13: 1st FDA-approved Oral Treatment for Endometriosis Pain in Over a Decade

    Neurocrine Biosciences discovered and developed through Phase II; AbbVie received FDA approval and responsible for commercialization 1st FDA-approved Oral Treatment for Women with Moderate to Severe Endometriosis Pain in Over a Decade; Launched in 2018 ▪ Rapid, Sustained Pain Relief Addresses three

  14. Slide 14: ORILISSA (elagolix) Overview

    ORILISSA® (elagolix) Overview Largest Ever Endometriosis Program Conducted to Date z 3,000,000 patients Efficacy: Label: AbbVie with moderate to severe Rapid and No boxed warnings or Collaboration endometriosis in U.S. Robust required monitoring ▪ Chronic and Painful Disease ▪ Efficacy as Early as 1

  15. Slide 15: Elagolix For Women's Health (Partnered with AbbVie)

    Elagolix For Women’s Health (Partnered with AbbVie) ORILISSA® Approved for Endometriosis; Uterine Fibroids NDA Submission Expected in 2H 2019 ENDOMETRIOSIS Most common UTERINE FIBROIDS pelvic growth Impacts affecting 10% >20% 9 million 7.5 million women with symptomatic uterine fibroids of of all wo

  16. Slide 16: Our Investigational Therapies

    Our Investigational Therapies

  17. Slide 17: Diversified Portfolio with Multi-Stage Pipeline

    Diversified Portfolio with Multi-Stage Pipeline Program/Therapy Disorder Stage of Development Partner 1 2 3 NDA Commercial Tardive Dyskinesia (Asia) Endometriosis (Worldwide) opicapone Parkinson’s Disease (NBIX Rights: U.S. & Canada) elagolix Uterine Fibroids (Worldwide) Congenital Adrenal NBI-74788

  18. Slide 18: Opicapone: NDA Accepted by FDA for Parkinson's Disease

    Opicapone: New Drug Application (NDA) Accepted by FDA for Parkinson’s Disease Target PDUFA Date of April 26, 2020; Discovered and Launched in Europe by BIAL; In-licensed in 2017 The Need: Parkinson’s Disease The Opportunity: Opicapone* 1 million ▪ Novel COMT inhibitor as adjunctive therapy to people

  19. Slide 19: Opicapone: Reducing OFF Time for Patients with Parkinson's Disease

    Opicapone: Reducing “OFF Time” For Patients with Parkinson’s Disease COMT Inhibition Reduces “OFF time” and Increases ▪ Parkinson’s Disease (PD): Lifelong, “ON time” Without Troublesome Dyskinesia Incurable, Progressive ▪ 2nd Most Common Neurodegenerative Disease Following Alzheimer’s Disease ▪ Appr

  20. Slide 20: Phase III BIPARK-1: Maintenance of Effect at One Year

    Phase III, BIPARK-1: Once Daily Opicapone Shows Maintenance of Effect at One Year* Mean Change in Absolute OFF time Double-blind Period Open-label Extension Period 12 Weeks 1-year 0 Placebo → OPC 50mg Switch to Opicapone Open-label LS MEAN (±SE) Change in OFF time 200mg ENT From DB Baseline (min) -6

  21. Slide 21: NBI-74788: Classic Congenital Adrenal Hyperplasia

    NBI-74788: Classic Congenital Adrenal Hyperplasia Positive Interim Phase II Results in Adults; Phase II Adaptive Pediatric Trial Initiated in Q3 The Need: Congenital Adrenal Hyperplasia The Opportunity: NBI-74788* Rare genetic disorder caused by enzyme ▪ Potent, selective, orally-active, non-peptide

  22. Slide 22: NBI-74788: Positive Interim Phase II Data (Adults)

    NBI-74788: Positive Interim Phase II Data (Adults) INTERIM RESULTS ▪ Reduction of at least 50 percent from baseline in 17-hydroxyprogesterone and adrenocorticotropic (ACTH) hormone levels in more than 50 percent of CAH patients treated for 14 days ▪ Meaningful reductions in other biomarkers, includi

  23. Slide 23: Elagolix: Pending NDA Submission for Uterine Fibroids in 2H 2019

    Elagolix: Pending NDA Submission for Uterine Fibroids in 2H 2019 Discovered & Developed by Neurocrine Biosciences to Phase II; Further Development by AbbVie The Need: Uterine Fibroids The Opportunity: Elagolix* ▪ Significant reduction in heavy menstrual 3 million women diagnosed with bleeding in up

  24. Slide 24: Elagolix: Polycystic Ovary Syndrome (PCOS)

    Elagolix: Polycystic Ovary Syndrome (PCOS) AbbVie Intends to Initiate Study The Need: PCOS The Opportunity: Elagolix* 3.5 million women of reproductive ▪ PCOS is one of the most common hormonal age with no approved therapies disorders in women of reproductive age, yet few treatment options are avail

  25. Slide 25: Voyager Therapeutics Collaboration

    Voyager Therapeutics Collaboration

  26. Slide 26: Voyager Gene Therapy Collaboration to Address Key Neuroscience Programs

    Voyager Gene Therapy Collaboration to Address Key Neuroscience Programs Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Programs: Neurocrine Biosciences gains development and commercializ

  27. Slide 27: VY-AADC: Gene Therapy for Parkinson's Disease

    VY-AADC: Gene Therapy for Parkinson’s Disease Developed by Voyager Therapeutics; First Patient Dosed in RESTORE-1 Phase II Trial in Q4 2018 The Need: Moderate to Advanced PD The Opportunity: VY-AADC* One million patients with PD in the U.S., ▪ One-time treatment restores AADC enzyme activity and imp

  28. Slide 28: VY-AADC (Study PD-1101): Improvements in Good ON Time

    VY-AADC (Study PD-1101): Durable, Clinically Meaningful Improvements in Good “ON Time” 2.8 Hour Improvement At 1 Year In Cohort 2/3 Combined And Phase II Eligible Group 4.0 (N=7) 3.0 2.8 2.6 2.5 2.3 1.9 2.4 2.0 2.1 1.7 1.6 Hours 1.0 0.0 -0.3 Dosage (vg) Cohort 1 (n=5) -1.0 Cohort 1: 7.5 x 1011 Cohor

  29. Slide 29: VY-FXN01: Gene Therapy for Friedreich's Ataxia

    VY-FXN01: Gene Therapy for Friedreich’s Ataxia Discovered by Voyager Therapeutics The Need: Friedreich’s Ataxia The Opportunity: VY-FXN01 ~6,400 ▪ One-time treatment to deliver the functional FXN patients impacted in the U.S. gene and restore frataxin levels to at least 50% of normal in relevant neu

  30. Slide 30: Our Vision for the Future

    Our Vision fomihe Future _ * = *

  31. Slide 31: 2019: A Defining Year of Significant Milestones

    2019: A Defining Year of Significant Milestones 2 NDA Submissions: Parkinson’s Disease & Uterine Fibroids Opicapone (Parkinson’s disease) COMPLETED Elagolix (Uterine fibroids) submitted by AbbVie Mid-2019 Advancing Congenital Adrenal Hyperplasia Program Positive interim results from Phase II Study (

  32. Slide 32: Neurocrine Biosciences: Well-Positioned for Sustained Growth

    Neurocrine Biosciences: Well-Positioned for Sustained Growth Strong Proven R&D Strategic Solid Financial Commercial with Strong Partnerships Position to Capabilities Multi-stage Invest Pipeline INGREZZA Blockbuster 3 Approved Potential; Medicines in ~$766MM Cash Experienced, 4 Indications in and Inv

  33. Slide 33: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2019 Corporate Presentation July 29, 2019 neurocrine.com NASDAQ: NBIX

Neurocrine Biosciences — Q2 2019 Earnings Presentation on 6ix